evipedia.ai
← Back

Maqui Berry for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Aristotelia chilensis, Maqui, Chilean Wineberry, Chilean Blackberry, Delphinol, MaquiBright

Motivation

Maqui berry is a small, dark purple fruit from the temperate rainforests of southern Chile and Argentina. It carries an unusually dense load of the deep-pigment compounds that give berries their color, and one of them, called delphinidin, is present at levels rarely matched by other fruits. That pigment profile is the reason a regional wild berry became an internationally traded supplement ingredient.

The Mapuche people of southern Chile have eaten the fruit and brewed its leaves for centuries, using both as an astringent remedy and a fever treatment. Modern interest arrived with the wave of tropical superfruit products in the 2000s, and two standardized extracts were later developed and tested in small human trials, one aimed at tear production and eye comfort, the other at blood sugar after meals.

This review examines what the human and laboratory evidence shows about maqui berry: the size and quality of the trials behind its two main claims, the mechanisms proposed for them, what is known and not known about safety, how products differ, and who funded the research.

Benefits - Risks - Protocol - Conclusion

High-level overviews of maqui berry and its anthocyanins (the purple pigment compounds that carry most of its activity), aimed at readers who want the whole picture before the trial-by-trial detail.

Note on coverage: of the six priority sources, only Life Extension has published directly relevant maqui content. Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser and Lifespan.io have not covered this berry, which is why four of the five items above are academic narrative reviews rather than expert commentary.

Grokipedia

  • Aristotelia chilensis

    Covers the plant’s botany, Mapuche traditional use, anthocyanin chemistry and commercial cultivation in Chile, giving background on the species that the clinical literature assumes rather than describes.

Examine

No dedicated Examine article for maqui berry exists. The site’s only coverage is a single research-feed study summary of a dry eye trial, which is a study digest rather than a dedicated page for the ingredient.

ConsumerLab

No dedicated ConsumerLab article or product review for maqui berry exists. Maqui is discussed only inside a broader answer on supplements for dry eye and a clinical update that links back to it, so the ingredient has no primary page of its own on the site.

Systematic Reviews

The two systematic reviews that cover maqui berry, one of human trials and one of animal work on the eye.

Trade-off coverage: both reviews address claimed benefits only. No systematic review or meta-analysis examines maqui berry’s harms, interactions, or the cost of substituting it for better-evidenced options, so the risk side of the trade-off is unrepresented in this literature.

Mechanism of Action

Maqui berry’s activity is attributed almost entirely to its anthocyanins, the water-soluble pigments that color the fruit; delphinidin glycosides make up the largest share.

Three mechanisms have human or animal support. First, delphinidins inhibit SGLT1 (sodium-glucose co-transporter 1, the pump that moves glucose from the gut into the blood) and, to a lesser degree, the digestive enzymes α-glucosidase and α-amylase, so less glucose enters the circulation after a starchy meal. Second, maqui extracts activate Nrf2 (a master switch that turns on the cell’s own antioxidant genes) and its downstream enzyme HO-1 (heme oxygenase-1, which clears cell-damaging heme and calms inflammation) while suppressing NF-κB (a protein complex that switches on inflammation genes); in the lacrimal (tear) glands this is the proposed basis for restored tear output. Third, a gut-hormone (incretin) effect has been proposed, in which anthocyanins increase release of GLP-1 (glucagon-like peptide-1, which stimulates insulin after eating).

A competing reading holds that intact anthocyanins are too poorly absorbed, under 1% of the ingested dose, to act systemically, and that the observed effects come from gut-level action and bacterial breakdown products such as protocatechuic and gallic acid.

Pharmacology in humans: this is a plant extract acting mainly in the gut lumen rather than on one systemic receptor. Delphinidin-3-O-glucoside peaks about one hour after ingestion and cyanidin-3-O-sambubioside about two hours, half-life is short at roughly two hours, plasma returns to baseline within eight hours, tissue levels are very low, and metabolism runs through gut microbiota followed by glucuronidation and methylation.

Historical Context & Evolution

Maqui was food and medicine long before it was a supplement. The Mapuche of south-central Chile ate the berries fresh and dried, fermented them into a mild alcoholic drink, and used leaf and fruit preparations as an astringent for diarrhea, a fever remedy, and a treatment for wounds, sore throat and stomach complaints. The fruit was also a dye.

Laboratory interest began with reports in the late 1990s that leaf extracts had strong free-radical scavenging activity, followed in 2002 by a Chilean finding that maqui juice fractions protected LDL (low-density lipoprotein, the cholesterol particle involved in artery plaque) from oxidation in the test tube and shielded human endothelial cells (the lining of blood vessels).

Commercial development followed the mid-2000s açaí boom. Maqui was marketed as the fruit with the highest ORAC score (oxygen radical absorbance capacity, a test-tube antioxidant ranking), a claim that lost standing when the US Department of Agriculture withdrew its ORAC database in 2012 on the grounds that the values had no established meaning in the body. That withdrawal did not overturn the underlying chemistry; it removed a marketing shortcut. Research then narrowed from generic antioxidant capacity to specific delphinidin actions, producing the two standardized extracts, one for tear production and one for post-meal glucose, that carry most of the human trial evidence today. Chilean domestication programs began in parallel, as wild harvesting could not meet export demand.

Expected Benefits

Medium 🟩 🟩

Increased Tear Production and Relief of Dry Eye Symptoms

Standardized maqui extract raises tear volume and eases dryness, grittiness and screen-related eye fatigue, apparently by protecting the tear glands from oxidative damage and lowering surface inflammation. Two placebo-controlled trials and one dose-comparison pilot, together fewer than 110 participants, all found higher Schirmer’s test values (a paper-strip measure of tear production) and better symptom scores; a 2026 systematic review judged this the most consistent maqui finding. Two of the three trials were run or funded by the extract manufacturer; the Indian trial was independent.

Magnitude: 60 mg/day for four weeks raised Schirmer’s test values by 6.4 ± 8.1 mm more than placebo (P = 0.005) in 74 screen workers; a 60-day pilot took tear volume from 18.7 to 27.1 mm.

Lower Post-Meal Blood Glucose and Insulin

Taken before a carbohydrate meal, delphinidin-rich extract blunts the glucose rise and the insulin response that follows, by slowing glucose uptake in the small intestine rather than by acting on the pancreas. Evidence comes from small crossover and dose-ranging trials in people with impaired glucose regulation; a 2026 systematic review called the acute effect the most reproducible metabolic finding, while chronic effects were inconsistent. Every acute trial used the same branded extract and involved its maker, so independent replication is missing.

Magnitude: A single 200 mg dose before rice lowered blood glucose at 60 and 90 minutes versus placebo (P < 0.05) in 10 glucose-intolerant adults; 60–180 mg doses cut fasting glucose and insulin dose-dependently within an hour.

Low 🟩

Reduced Markers of Oxidative Stress

Four weeks of 450 mg extract daily lowered oxidized LDL and a urinary marker of fat-oxidation damage in overweight adults and smokers; two weeks normalized hydrogen peroxide and interleukin-6 (an inflammation signal) in the exhaled breath of light smokers. Both compared against baseline, not placebo.

Magnitude: Significant within-group falls in oxidized LDL and urinary F2-isoprostanes (a urine marker of fat-oxidation damage) at four weeks (P < 0.05) in 42 adults; the trial published no placebo-adjusted effect size.

Lower Long-Term Blood Sugar and Improved Cholesterol Profile ⚠️ Conflicted

In prediabetic adults taking 180 mg daily for three months, HbA1c (average blood sugar over about three months) fell steadily, LDL fell and HDL (high-density lipoprotein, the protective cholesterol particle) rose. The trial had no control group and 31 participants; the 2026 systematic review found chronic effects modest and inconsistent.

Magnitude: HbA1c fell from 5.65% to 5.35% over three months (−0.30 percentage points, P = 0.003), with LDL reduced at three months (P = 0.001), in 31 prediabetic adults.

Improved Autonomic Balance and Perceived Mental Wellbeing

A month of 1,000 mg daily of a maqui-based product raised heart rate variability indices reflecting parasympathetic (rest-and-digest) activity and improved the mental component of a quality-of-life questionnaire. The study was single-blind with 15 people per arm, and the authors note an unusual heatwave confounded several outcomes.

Magnitude: Autonomic coordination rose (P = 0.05) and the mental quality-of-life score improved (P = 0.02) in 30 healthy adults; the study reported no effect size for either measure.

Speculative 🟨

Protection Against Bone Loss

A delphinidin-enriched maqui extract stimulated bone-building cells, suppressed bone-resorbing cells and increased trabecular bone volume in mice with osteopenia (reduced bone density). No human bone endpoint has been measured.

Improved Insulin Sensitivity and Fat Tissue Remodelling

Freeze-dried maqui reduced insulin resistance, induced browning of white fat and suppressed liver fat synthesis in mice on a high-fat diet. Human trials have not tested body composition or insulin sensitivity directly.

Protection Against Bowel Inflammation

A maqui water extract eased colitis (inflammation of the large bowel), lowered inflammatory markers and rebalanced gut bacteria in mice with chemically induced disease. No human bowel endpoint has been studied.

Memory Protection and Neuroprotection

Maqui extract improved memory and lowered brain oxidative stress in ozone-exposed rats, and fruit extracts act on Alzheimer-related mechanisms in cell models. No cognitive trial in humans exists.

Skin Photoprotection

Maqui extract limited ultraviolet-induced damage in cultured human skin fibroblasts, the basis for its use in oral and topical cosmetic products. No human skin endpoint has been tested.

Benefit-Modifying Factors

  • Baseline metabolic and tear status: The measured effects are largest where there is room to move — impaired glucose regulation, low tear volume, elevated oxidative markers. In one beverage trial antioxidant capacity rose only in those with the poorest baseline antioxidant status.

  • Gut microbiome composition: Under 1% of anthocyanins is absorbed intact; most benefit is thought to travel through bacterial breakdown products. Recent antibiotic courses or low microbial diversity plausibly reduce the yield of those metabolites.

  • Genetic variation in phenolic handling: COMT (catechol-O-methyltransferase, an enzyme that adds methyl groups to catechol compounds) and UGT (UDP-glucuronosyltransferase, which tags compounds for excretion) variants alter anthocyanin clearance rate, and therefore exposure at any given dose.

  • Sex-based differences: Plasma bioactive levels after a maqui-lemon beverage differed by sex, and dry eye is markedly more prevalent in women, so the ocular benefit has a larger addressable population in women.

  • Pre-existing health conditions: Prediabetes, diagnosed dry eye disease and heavy screen exposure define the populations in which benefit was actually demonstrated. Healthy, metabolically fit adults were not studied, and no benefit is established for them.

  • Age-related considerations: Tear production and insulin sensitivity both decline with age, widening the potential gain in adults over 50. Against this, older adults have less diverse gut flora, which may reduce metabolite formation.

Potential Risks & Side Effects

Low 🟥

Low Blood Sugar When Combined with Glucose-Lowering Treatment

Maqui blocks intestinal glucose uptake, so it adds to insulin and sulfonylureas (oral diabetes drugs that push the pancreas to release insulin). No low-blood-sugar episode has been reported in a maqui trial, but all trials excluded people on such treatment, so the risk is inferred from mechanism.

Magnitude: Not quantified in available studies. No trial has enrolled people taking glucose-lowering drugs alongside maqui, so neither the frequency nor the depth of any blood-sugar drop has been measured; only the underlying glucose-transport effect is documented.

Reduced Absorption of Iron from Plant Foods

Polyphenols of the kind maqui concentrates bind non-heme iron (the form found in plants and supplements) in the gut and cut its absorption when taken with a meal. This is a class effect measured for tea, cocoa and berry beverages; no study has quantified it for maqui specifically.

Magnitude: Polyphenol-rich beverages reduced non-heme iron absorption by roughly 60–90% when drunk with a test meal in controlled absorption studies; the corresponding figure for maqui has never been measured.

Variable Potency and Contamination in Unstandardized Products

Anthocyanin content of wild maqui varies by harvest region and degrades with heat and light, and marker-based analysis of a commercial maqui ingredient was developed precisely because identity and potency could not be assumed. Botanical powders as a category also carry heavy-metal and adulteration risk.

Magnitude: Total anthocyanin content of wild maqui ranged from 6.6 to 15.0 g/kg fresh weight across four Chilean regions, a 2.3-fold spread, so the delivered dose from an unstandardized powder is unpredictable (Fredes et al., 2014); no survey reports a contamination rate for maqui products specifically, and the adulteration and heavy-metal data are category-wide.

Speculative 🟨

Increased Bleeding Tendency with Blood-Thinning Drugs

Maqui leaf and unripe-fruit extracts inhibited platelet clumping in laboratory blood samples. Whether ripe-fruit supplements affect bleeding in people taking anticoagulants (blood thinners) has never been tested.

Digestive Discomfort at Gram-Level Powder Doses

Whole-berry powders supply several grams of fiber and tannins per serving, which can loosen or tighten stools. No maqui trial has reported digestive complaints, and traditional use was as an anti-diarrheal.

Alkaloid Effects from Leaf Preparations

Maqui leaves contain indole alkaloids that modulate nerve sodium channels in isolated tissue. Fruit extracts contain little of these compounds, but leaf teas are not equivalent to fruit supplements.

Hypersensitivity Reactions

No allergic reaction to maqui has been published, and drug references list no adverse reactions. Sensitivity to a novel plant food remains possible, particularly in people reacting to other berries.

Risk-Modifying Factors

  • Genetic variation in phenolic handling: Slow-clearance COMT and UGT variants raise systemic exposure at a fixed dose, which matters more for the theoretical platelet and glucose interactions than for gut-level effects.

  • Baseline biomarker levels: Low ferritin, low fasting glucose, a platelet count below 150 × 10⁹/L or an already-therapeutic clotting time all shrink the safety margin for the iron, glucose and bleeding concerns respectively.

  • Sex-based differences: Menstruating women carry lower iron stores and a higher rate of iron deficiency, making the polyphenol-iron interaction the one risk with a clear sex asymmetry. No sex difference in adverse events has been reported.

  • Pre-existing health conditions: Treated diabetes, bleeding disorders, planned surgery, and iron-deficiency anemia each convert a theoretical interaction into a plausible one. Advanced kidney or liver disease has never been studied with maqui.

  • Age-related considerations: Adults over 65 more often take anticoagulants and glucose-lowering drugs simultaneously, so the two main theoretical interactions cluster in the older end of the target range. Age itself has no documented effect on tolerance.

Key Interactions & Contraindications

  • Insulin and sulfonylureas (glipizide, glyburide, glimepiride): Caution; additive glucose lowering can produce symptomatic low blood sugar. Mitigation is more frequent glucose checks for the first two weeks and dose review by the prescribing clinician.

  • Other glucose-lowering agents (metformin, acarbose, empagliflozin): Caution; overlapping mechanisms, most directly with acarbose, which also blocks carbohydrate digestion. Consequence is exaggerated post-meal glucose lowering and, with acarbose, more gas and bloating.

  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel): Caution on theoretical grounds; possible additive bleeding risk from platelet inhibition seen only in vitro. Mitigation is avoiding gram-level powder doses and stopping 14 days before surgery.

  • Over-the-counter aspirin and NSAIDs (non-steroidal anti-inflammatory painkillers such as ibuprofen and naproxen): Caution; the same theoretical additive antiplatelet effect, plus shared gastric irritation with high-tannin powders. Taking maqui with food and keeping to extract doses limits both.

  • Over-the-counter iron supplements (ferrous sulfate, ferrous bisglycinate): Monitor; polyphenols bind non-heme iron and reduce absorption. Separating maqui and iron by at least two hours removes most of the interaction.

  • Supplements with additive glucose-lowering effects: Berberine, chromium picolinate, cinnamon extract, bitter melon and alpha-lipoic acid. Caution; combined use can lower post-meal glucose further than intended, particularly when stacked with a low-carbohydrate meal.

  • Supplements with additive antiplatelet effects: Fish oil above 3 g/day, ginkgo, garlic extract, high-dose vitamin E and nattokinase. Caution; theoretical bleeding risk, relevant mainly around surgery, dental extraction or existing anticoagulation.

  • Other interventions: Prolonged fasting, ketogenic diets and post-meal exercise all lower glucose through separate routes. Monitor rather than avoid; the combination is additive and occasionally produces reactive fatigue in lean, insulin-sensitive users.

Populations who should avoid Maqui Berry:

  • Pregnant and breastfeeding women — no safety or efficacy data exist for either state in any species-relevant human study.
  • Anyone with surgery scheduled within 14 days, or an invasive dental procedure within 7 days.
  • People with a platelet count below 50 × 10⁹/L, or an inherited bleeding disorder such as von Willebrand disease.
  • People with type 1 diabetes on insulin who are not using continuous or frequent glucose monitoring.
  • Anyone with a known allergy to maqui or other Elaeocarpaceae-family plants.

Risk Mitigation Strategies

  • Low starting dose with slow escalation: Studied protocols open at 30–60 mg/day of standardized extract for two weeks before moving to 180 mg/day, so any digestive or glucose response appears at a dose that is easy to reverse.

  • Glucose monitoring alongside diabetes treatment: Fasting and two-hour post-meal readings daily for the first 14 days detect the additive glucose lowering that mechanism predicts but no trial has measured.

  • Two-week washout before surgery: Stopping maqui 14 days ahead covers platelet turnover and removes the theoretical bleeding risk from the in-vitro antiplatelet activity of maqui extracts.

  • Two-hour separation from iron: Taking maqui at least two hours away from iron supplements or iron-rich plant meals prevents the polyphenol-iron binding that reduces non-heme iron absorption.

  • Standardized, third-party-tested fruit extract: A delphinidin-standardized extract carrying a heavy-metal certificate of analysis addresses both unpredictable potency and the contamination risk of unstandardized botanical powders.

  • Fruit-derived products only: Leaf preparations carry the indole alkaloids with nerve-channel activity; intake restricted to fruit extracts or berry powder avoids that exposure entirely.

Therapeutic Protocol

  • Ocular protocol: 60 mg/day of delphinidin-standardized extract, taken once daily for at least 8 weeks. This is the dose and duration that produced measurable tear increases in both eye trials.

  • Glycemic protocol: 180 mg/day of standardized extract, or 200 mg taken 30–60 minutes before the largest carbohydrate meal. Higher single doses lowered glucose peaks more consistently than the lowest doses.

  • Whole-food approach: 2–5 g/day of freeze-dried berry powder in place of extract. This is the traditional and food-first alternative; anthocyanin delivery is lower and far less predictable than a standardized capsule.

  • Competing approaches: Ophthalmology practice treats dry eye with artificial tears, omega-3s and anti-inflammatory drops. Neither the drop-first nor the oral-antioxidant approach has been shown superior; they are not mutually exclusive.

  • Who popularized each approach: The eye extract was developed by Oryza Oil & Fat in Japan and popularized in the US by Life Extension, which sells it; the glucose extract came from Chilean work with MNL-Chile.

  • Best time of day: Glycemic use is meal-anchored, so before the largest carbohydrate meal. Ocular use was tested as a single morning dose; no circadian advantage has been demonstrated for either.

  • Half-life and clearance: Plasma anthocyanins peak at one to two hours with a half-life near two hours and return to baseline by eight hours, which is why gut-level effects are dose-timed rather than steady-state.

  • Single versus split dosing: Eye trials used one daily capsule successfully. For glucose control the short half-life argues for dosing before each major carbohydrate meal rather than one morning dose.

  • Genetic polymorphisms: COMT and UGT variants alter anthocyanin clearance; SGLT1 variants plausibly alter the glucose response. None has been used to stratify a maqui trial, so no genotype-guided dosing exists.

  • Sex-based differences: Plasma bioactive levels after a maqui beverage differed between men and women, but no trial has titrated dose by sex, and both eye trials enrolled both sexes at the same dose.

  • Age-related considerations: No dose adjustment by age has been studied. Older adults with lower baseline tear volume may need the full 8-week course before change is measurable on a Schirmer’s test.

  • Baseline biomarkers guide selection: Fasting glucose and HbA1c identify who might gain metabolically; a Schirmer’s test identifies who might gain ocularly. Normal values on both predict little measurable benefit.

  • Pre-existing conditions: Prediabetes and dry eye disease are the two states in which effects were demonstrated. Gut dysbiosis (a disrupted balance of gut bacteria) plausibly reduces response by limiting metabolite formation.

Discontinuation & Cycling

  • Lifelong or short-term: Effects appear exposure-dependent rather than cumulative, so use is best framed as ongoing while the target problem persists, not as a course with a defined endpoint.

  • Effects reverse on stopping: Oxidative stress markers had returned to baseline 40 days after supplementation ended in the oxidative stress trial, and the acute glucose effect lasts only hours.

  • Withdrawal effects: None reported in any trial, and none is mechanistically expected; there is no receptor adaptation, dependence signal or rebound described for anthocyanins.

  • Tapering: Not applicable. No trial tapered, and abrupt cessation produced no adverse events in trials lasting up to three months.

  • Cycling: No evidence supports cycling. Continuous daily use was studied to three months without loss of effect, and no tolerance to the glucose or tear effects has been described.

Sourcing and Quality

  • Standardization is the single most important criterion: The two extracts with human data are standardized to delphinidin content — one to at least 25% delphinidin glycosides and 35% total anthocyanins. Unstandardized “maqui powder” has no dose equivalence to either.

  • Third-party testing: A certificate of analysis showing anthocyanin content by HPLC (high-performance liquid chromatography, a laboratory method that separates and quantifies compounds) plus heavy-metal screening is the practical quality bar; NSF and USP marks indicate audited manufacturing.

  • Reputable sources: The clinically tested ingredients are supplied by Oryza Oil & Fat and Anklam Extrakt; finished products carrying them include Life Extension, NOW and Swanson lines. Ingredient branding on the label is the marker to look for.

  • Form and storage: Anthocyanins degrade with heat, light and oxygen. Freeze-dried or microencapsulated powders in opaque, sealed containers stored cool retain content better than bulk juice powders sold in clear packaging.

  • Provenance and adulteration: Anthocyanin content varies by Chilean harvest region and season, and cheaper berries can substitute for maqui in powders. Chilean origin plus quantified delphinidin content on the label reduces both problems.

Practical Considerations

  • Time to effect: The glucose effect is acute, appearing within 30–60 minutes of a single dose. Tear production changes took 30 days in trials and were larger at 60 days; oxidative markers shifted by 4 weeks.

  • Common pitfall — token doses in blends: “Superfruit” powders and greens blends often contain a fraction of a gram of maqui, far below any tested dose, while carrying the claims generated by 60–180 mg of standardized extract.

  • Common pitfall — wrong timing: For glucose the extract must precede the meal; taken afterwards it cannot block intestinal uptake of a bolus that has already arrived. Ocular use is unaffected by timing.

  • Common pitfall — expecting weight loss: Fat browning and anti-obesity findings are entirely from mice. No human trial has reported weight or body composition change with maqui supplementation.

  • Regulatory status: In the US maqui is a dietary supplement, not FDA-approved for any disease, and structure-function claims only. No approved health claim exists in the EU, where anthocyanin claims have been rejected.

  • Cost and accessibility: Standardized extract runs roughly $0.30–1.00 per day, comparable to a common vitamin. Fresh berries are essentially unavailable outside Chile; powder and capsules ship internationally without restriction.

Interaction with Foundational Habits

  • Sleep: No direct effect; maqui contains no stimulant and no trial reported sleep disturbance. An indirect route exists in that relieving evening eye dryness and fatigue reduces one common source of discomfort during late screen use, though this was never measured as a sleep endpoint.

  • Nutrition: Direct and meal-dependent. The glucose effect requires dosing before a carbohydrate-containing meal, so it pairs with higher-carbohydrate eating rather than replacing dietary change. Countervailing consideration: taking it with iron-rich plant meals or iron supplements reduces non-heme iron absorption, so separate those by two hours.

  • Exercise: Direction uncertain and untested. High-dose antioxidant supplements as a class can blunt some training adaptations by suppressing the oxidative signal that drives them; whether maqui doses are high enough to matter is unknown. Dosing away from training sessions is the conservative option pending data.

  • Stress management: Possibly potentiating, on thin evidence. One small single-blind trial found improved heart rate variability, a measure of parasympathetic (rest-and-digest) tone, and a better mental quality-of-life score after a month. No cortisol measurement exists, and the trial’s own authors flagged confounding by a heatwave.

Monitoring Protocol & Defining Success

Baseline testing establishes whether either of maqui’s two evidenced effects is measurable in a given person. Fasting glucose, HbA1c and fasting insulin capture the metabolic starting point; a standard lipid panel provides the cholesterol baseline; and hs-CRP (high-sensitivity C-reactive protein, a general inflammation marker) is also recorded. Where the goal is eye comfort, a Schirmer’s test and tear break-up time recorded by an eye clinician give the objective baseline, since self-reported dryness tracks measured tear volume poorly. Ferritin is worth recording in menstruating women and others with borderline iron stores.

Ongoing monitoring is light: the metabolic panel is repeated at 12 weeks, then every six to twelve months during continued use, and tear measurements at 8 weeks, since trial responses emerged between 30 and 60 days. Ferritin is rechecked annually.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 75–90 mg/dL Primary metabolic target of the extract 8–12 h fast; conventional labs flag only above 100 mg/dL
HbA1c 4.8–5.4% Average glucose exposure over ~3 months No fasting needed; falsely low with anemia or short red-cell lifespan; conventional labs call anything below 5.7% normal
Fasting insulin 2–6 µIU/mL Detects compensation masking normal glucose Draw with glucose in the same fasting sample; conventional reference ranges extend to roughly 25 µIU/mL
HOMA-IR < 1.5 Insulin resistance index HOMA-IR is the homeostatic model assessment of insulin resistance, calculated from fasting glucose and insulin; no extra draw; conventional cut-off is 2.5
hs-CRP < 1.0 mg/L General inflammation, secondary target High-sensitivity assay (hs-) required; repeat if a recent infection; conventional low-risk cut-off is below 3.0 mg/L
Oxidized LDL No established target; track change from own baseline The marker that moved in the oxidative stress trial Specialty assay, not on routine panels; fasting sample preferred
LDL cholesterol < 100 mg/dL, lower with risk factors Secondary outcome in the three-month trial Standard fasting lipid panel; pair with ApoB (apolipoprotein B, a count of cholesterol-carrying particles) where available
Schirmer’s test > 10 mm in 5 minutes Objective tear production, primary ocular endpoint Performed by a clinician; avoid drops for 2 h beforehand
Tear break-up time > 10 seconds Tear film stability, complements Schirmer’s Same visit as Schirmer’s; measured before any dilating drops
Ferritin 50–100 ng/mL (women), 50–150 ng/mL (men) Iron stores, the one plausible depletion risk Rises with inflammation; interpret alongside hs-CRP; conventional labs flag deficiency only below about 15–30 ng/mL

Qualitative markers worth tracking alongside the labs:

  • Eye comfort at the end of a screen-heavy day, and how often artificial tears are reached for
  • Visual clarity and blink frequency during sustained close work
  • Post-meal energy: whether the mid-afternoon slump after a carbohydrate-heavy lunch softens
  • Digestive comfort, particularly with gram-level berry powder rather than capsules
  • Subjective stress recovery and evening calm, the outcome suggested by the heart rate variability trial

Emerging Research

  • Combination with omega-3 for inflammation: A completed Arizona State University trial (NCT04914312, 32 participants) tested maqui berry extract with omega-3 fatty acids against interleukin-6, interleukin-1 beta and tumor necrosis factor as primary endpoints; results are not yet published.

  • Vascular function dose-finding: A University of Memphis study (NCT07196059, 10 participants) compared 60, 120 and 180 mg of the branded extract against placebo on endothelial function and blood nitrate/nitrite, the first attempt to establish a vascular dose-response.

  • Food-format delivery: A completed study of maqui gummy candies (NCT07373795, 10 participants with overweight or insulin resistance) uses blood glucose as its primary endpoint, testing whether a confectionery format preserves the acute glucose effect seen with capsules.

  • Mood and anxiety: “Maqui Mind” (NCT07504081, 30 participants, active and not recruiting) measures change in perceived anxiety, extending the single heart rate variability finding into a mental-health endpoint for the first time.

  • Antifungal use in diabetes: A University of Belgrade trial (NCT05916729, 90 participants, Phase 4) tests maqui berry extract against oral thrush in people with and without diabetes, an application entirely outside the metabolic and ocular literature.

  • Evidence that could weaken the case: The 2026 systematic review by Arce-Johnson et al. found chronic supplementation produced modest and inconsistent effects on long-term blood sugar, lipids and other cardiometabolic markers; an adequately powered chronic trial without manufacturer involvement could remove the remaining support for daily use.

  • Kidney protection as an open question: A 2025 narrative review by Tiscornia et al. argues maqui anthocyanins could slow chronic kidney disease progression, but the supporting work is preclinical and no trial in kidney patients has begun.

  • Bioavailability engineering: Work on nanoencapsulation of maqui extract (Andrade et al., 2024) targets the field’s central weakness, under 1% absorption of intact anthocyanins, and would change dose expectations if it succeeds.

Conclusion

Maqui berry is a Chilean fruit whose dark pigments, especially one called delphinidin, are more concentrated than in almost any other berry. Two claims rest on human testing rather than laboratory work alone: that a standardized extract increases tear production and relieves dry, tired eyes, and that a dose taken before a meal blunts the rise in blood sugar and insulin that follows it. Both rest on small and short trials, and a recent review of all the human evidence rated its certainty as moderate at best and often much lower.

The safety picture is quiet rather than reassuring. No side effect has been documented, no interaction is established, and no product reference lists a reason to avoid it; equally, the longest human use studied is three months, nothing is known about use in pregnancy, and the plausible overlaps with blood-sugar and blood-thinning treatments have never been tested in people.

A structural caveat runs through the field: most of the human evidence was produced by, or with, the two companies selling the standardized extracts, and the most visible consumer writing comes from a company that sells the product. The independent eye trial run by a hospital group is the notable exception, and its results pointed the same way.

Top - Benefits - Risks - Protocol